Company Encyclopedia
View More
name
GE HealthCare Tech
GEHC.US
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products.
1.366 T
GEHC.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking44/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE24.21%A
    • Profit Margin10.95%B
    • Gross Margin38.67%B
  • Growth ScoreC
    • Revenue YoY3.51%C
    • Net Profit YoY32.30%B
    • Total Assets YoY6.71%B
    • Net Assets YoY20.07%A
  • Cash ScoreC
    • Cash Flow Margin913.63%B
    • OCF YoY3.51%C
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreD
    • Gearing Ratio71.71%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GE Healthcare’s Intelerad Acquisition: Balancing Long-term Growth with Short-term EPS Dilution

    J.P. Morgan analyst Robbie Marcus maintains a Hold rating on GE Healthcare stock due to its Intelerad acquisition, which promises long-term growth but short-term EPS dilution. The acquisition aligns with GE Healthcare's strategy to boost recurring revenue. Regulatory approvals are needed before completion in 2026. Bank of America also holds a neutral stance with an $82 price target.

    Tip Ranks·
    US
    GEHC
    +3.37%
    Tip Ranks·
    US
    GEHC
    +3.37%

    GE HealthCare Technologies Inc. Stock Rises Thursday, Outperforms Market

    Shares of GE HealthCare Technologies Inc. rose 3.37% to $74.75 on Thursday, outperforming the market despite a rough trading session. This marks the stock's third consecutive day of gains. Trading volume was significantly higher than the 50-day average. The stock is still 21.15% below its 52-week high of $94.80 reached on February 13th.

    Dow Jones·
    US
    GEHC
    +3.37%
    Dow Jones·
    US
    GEHC
    +3.37%

    GE Healthcare Technologies to Acquire Intelerad for $2.30 Billion

    GE Healthcare Technologies to Acquire Intelerad for $2.30 Billion

    marketscreener·
    US
    GEHC
    +3.37%
    marketscreener·
    US
    GEHC
    +3.37%

    GE Healthcare: Will acquire medical imaging software supplier Intelerad for $2.3 billion in cash

    Wallstreetcn·
    US
    GEHC
    +3.37%
    Wallstreetcn·
    US
    GEHC
    +3.37%

    HgCapital Trust Exits Intelerad in Sale to GE HealthCare

    HgCapital Trust plc has sold Intelerad, a leader in medical imaging software, to GE HealthCare for approximately £52 million, marking a £20 million increase over its previous value. Under Hg's ownership, Intelerad's revenue grew 3.5 times, serving over 1,500 customers and supporting 230 million medical exams annually. The transaction aims to enhance imaging workflows and diagnostic efficiency. Terms were undisclosed.

    Reuters·
    US
    GEHC
    +3.37%
    Reuters·
    US
    GEHC
    +3.37%